These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23465957)

  • 1. Changes in bone matrix mineralization after growth hormone treatment in children and adolescents with chronic kidney failure treated by dialysis: a paired biopsy study.
    Nawrot-Wawrzyniak K; Misof BM; Roschger P; Pańczyk-Tomaszewska M; Ziółkowska H; Klaushofer K; Fratzl-Zelman N
    Am J Kidney Dis; 2013 May; 61(5):767-77. PubMed ID: 23465957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort.
    Misof BM; Roschger P; Gabriel D; Paschalis EP; Eriksen EF; Recker RR; Gasser JA; Klaushofer K
    J Bone Miner Res; 2013 Mar; 28(3):442-8. PubMed ID: 23044788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Misof BM; Paschalis EP; Blouin S; Fratzl-Zelman N; Klaushofer K; Roschger P
    J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormally High and Heterogeneous Bone Matrix Mineralization After Childhood Solid Organ Transplantation: A Complex Pathology of Low Bone Turnover and Local Defects in Mineralization.
    Fratzl-Zelman N; Valta H; Pereira RC; Misof BM; Roschger P; Jalanko H; Wesseling-Perry K; Klaushofer K; Mäkitie O
    J Bone Miner Res; 2017 May; 32(5):1116-1125. PubMed ID: 28214296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragility fractures in men with idiopathic osteoporosis are associated with undermineralization of the bone matrix without evidence of increased bone turnover.
    Fratzl-Zelman N; Roschger P; Misof BM; Nawrot-Wawrzyniak K; Pötter-Lang S; Muschitz C; Resch H; Klaushofer K; Zwettler E
    Calcif Tissue Int; 2011 May; 88(5):378-87. PubMed ID: 21318401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).
    Roschger P; Lombardi A; Misof BM; Maier G; Fratzl-Zelman N; Fratzl P; Klaushofer K
    J Bone Miner Res; 2010 Jan; 25(1):48-55. PubMed ID: 19580465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
    Weber M; Roschger P; Fratzl-Zelman N; Schöberl T; Rauch F; Glorieux FH; Fratzl P; Klaushofer K
    Bone; 2006 Sep; 39(3):616-22. PubMed ID: 16644299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased heterogeneity of bone matrix mineralization in pediatric patients prone to fractures: a biopsy study.
    Tamminen IS; Misof BM; Roschger P; Mäyränpää MK; Turunen MJ; Isaksson H; Kröger H; Mäkitie O; Klaushofer K
    J Bone Miner Res; 2014; 29(5):1110-7. PubMed ID: 24166885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normative data on mineralization density distribution in iliac bone biopsies of children, adolescents and young adults.
    Fratzl-Zelman N; Roschger P; Misof BM; Pfeffer S; Glorieux FH; Klaushofer K; Rauch F
    Bone; 2009 Jun; 44(6):1043-8. PubMed ID: 19268565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased bone matrix mineralization in treatment-naïve children with inflammatory bowel disease.
    Misof BM; Roschger P; Klaushofer K; Rauch F; Ma J; Mack DR; Ward LM
    Bone; 2017 Dec; 105():50-56. PubMed ID: 28705682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term recombinant human growth hormone use in Australian children with renal disease.
    Crompton CH;
    Nephrology (Carlton); 2004 Oct; 9(5):325-30. PubMed ID: 15504147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study.
    Misof BM; Patsch JM; Roschger P; Muschitz C; Gamsjaeger S; Paschalis EP; Prokop E; Klaushofer K; Pietschmann P; Resch H
    J Bone Miner Res; 2014 Feb; 29(2):440-9. PubMed ID: 23832525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of recombinant human growth hormone on urea and creatinine kinetics and selected dialysis adequacy parameters in children with end-stage renal failure treated with peritoneal dialysis].
    Jedrzejowski A; Dyras P; Pańczyk-Tomaszewska M; Mizerska-Wasiak M; Roszkowska-Blaim M; Pietrzyk JA; Gałazka B
    Pol Merkur Lekarski; 2002 Sep; 13(75):191-5. PubMed ID: 12474568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone matrix mineralization is preserved during early perimenopausal stage in healthy women: a paired biopsy study.
    Misof BM; Roschger P; Blouin S; Recker R; Klaushofer K
    Osteoporos Int; 2016 May; 27(5):1795-803. PubMed ID: 26650378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of recombinant growth hormone treatment in children with end-stage renal disease on regular hemodialysis.
    Youssef DM
    Saudi J Kidney Dis Transpl; 2012 Jul; 23(4):755-64. PubMed ID: 22805388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of bone mineralization density distribution (BMDD) in cortical and cancellous bone within the iliac crest of healthy premenopausal women.
    Misof BM; Dempster DW; Zhou H; Roschger P; Fratzl-Zelman N; Fratzl P; Silverberg SJ; Shane E; Cohen A; Stein E; Nickolas TL; Recker RR; Lappe J; Bilezikian JP; Klaushofer K
    Calcif Tissue Int; 2014 Oct; 95(4):332-9. PubMed ID: 25134800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
    Zoehrer R; Roschger P; Paschalis EP; Hofstaetter JG; Durchschlag E; Fratzl P; Phipps R; Klaushofer K
    J Bone Miner Res; 2006 Jul; 21(7):1106-12. PubMed ID: 16813531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization.
    Misof BM; Roschger P; Dempster DW; Zhou H; Bilezikian JP; Klaushofer K; Rubin MR
    J Bone Miner Res; 2016 Jan; 31(1):180-9. PubMed ID: 26111772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency.
    Cavallo L; Gurrado R; Zecchino C; Manolo F; De Sanctis V; Cisternino M; Caruso-Nicoletti M; Galati M
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():845-9. PubMed ID: 10091155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.